BSD Medical Corporation (NASDAQ:BSDM) jumped 45.51% up to $2.43 on news the Journal of the National Cancer Institute published an article on the evolving role of hyperthermia in cancer therapy titled, “International Study of Hyperthermia Spurs Hope in U.S.” The article stated that, “Successful use of targeted heat therapy with chemotherapy in treatment of soft-tissue sarcoma has given US advocates of local hyperthermia new hope that the treatment they so believe in will now be taken seriously.” Last fall a Phase III study, which applied the BSD-2000 Hyperthermia System, showed that patients with high risk soft-tissue sarcomas were 30% more likely to be alive and cancer free almost three years after beginning the treatment if heat therapy was added to chemotherapy. Headquartered in Salt Lake City, Utah, BSD Medical Corporation develops, manufactures, commercializes, and services systems used for therapeutic treatments of cancer and other diseases.   The company is specialized in researching and developing therapeutics which bio-enhance current treatments.

Repros Therapeutics Inc. (NASDAQ:RPRX) gained 25.97% up to $0.94 on news the company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the company may begin its Investigational New Drug Application for the study of oral Androxal in the treatment of hypogonadal men with Type II Diabetes with a Phase IIa trial. Based in The Woodlands, Texas, Repros Therapeutics is a development-stage biopharmaceutical company developing drug therapies for the treatment of serious female pelvic conditions, such as treatment of uterine fibroids, anaemia associated with excessive menstrual bleeding relating to uterine fibroids, and anaemia associated with uterine fibroids and endometriosis.  Repros Therapeutics has three late stage drug candidates in trials including Androxal, a hormone treatment of for low testosterone levels in men.  RPRX is surging on heavy volume with 9,067,032 shares trading actively.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Repros Therapeutics Inc. (NASDAQ:RPRX) gained 57.74% up to $1.09 on news Repros received guidance from  the Division of Reproductive and Urologic Products of the FDA on January 25th, 2010. The focus of the teleconference meeting was to know the FDA’s current position regarding the use of Repros’ oral Androxal for the treatment of men with secondary hypogonadism while preserving fertility. The company’s data supports the notion that the negative feedback of exogenous testosterone administered by any route suppresses the hypothalamic–pituitary axis and causes spermatogenesis. The FDA requested a label to better identify individuals Repros believes will benefit from the use of Androxal. The FDA also requested a review of the literature of the incidence of infertility associated with the use of exogenous testosterone as supportive of the Repros’ data.  If the FDA is satisfied by the submission, there will be no more additional clarifying meetings regarding Androxal. Based in The Woodlands, Texas, Repros Therapeutics is a development-stage biopharmaceutical company developing drug therapies for the treatment of serious female pelvic conditions, such as treatment of uterine fibroids, anaemia associated with excessive menstrual bleeding relating to uterine fibroids, and anaemia associated with uterine fibroids and endometriosis.  Repros Therapeutics has three late stage drug candidates in trials including Androxal, a hormone treatment of for low testosterone levels in men.  RPRX is surging on heavy volume with 9,850,267 shares moving actively, and is trading well above its 50 day moving average of $0.74.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

QLT Inc. (USA) (NASDAQ:QLTI) rose 15.97% up to $4.37 on news QLT has settled a lawsuit brought by Massachusetts General Hospital.  QLT will pay $20 million to the Massachusetts General Hospital which has agreed to drop their lawsuit against QLT. QLT developed Visudyne, which treats age-related vision conditions, in cooperation with Massachusetts General and the Massachusetts Eye and Ear Infirmary.  Massachusetts General launched its suit in February on grounds that it was entitled to higher revenues from Visudyne sales. Headquartered in Vancouver, Canada, QLT Inc is a biopharmaceutical company which discovers, develops, and commercializes pharmaceutical products, primarily for ophthalmology and eye care.  The company’s Visudyne photosensitizer treats eye disease, known as age related macular degeneration; and severe near-sightedness, and presumed ocular histoplasmosis or other eye diseases.

Repros Therapeutics Inc. (NASDAQ:RPRX) gained 16.90% up to $0.822 on no news with 1,048,129 shares moving this afternoon. Based in The Woodlands, Texas, Repros Therapeutics is a development-stage biopharmaceutical company developing drug therapies for the treatment of serious female pelvic conditions, such as treatment of uterine fibroids, anaemia associated with excessive menstrual bleeding relating to uterine fibroids, and anaemia associated with uterine fibroids and endometriosis.  Repros Therapeutics has three late stage drug candidates in trials.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

Repros Stock Surges On Positive Trial Results

The hot stock information of the day includes:   RPRX, TWMC, TLR

Repros Therapeutics Inc. (NASDAQ:RPRX) skyrocketed 124.73% up to $2.00 on news disclosed late yesterday. The company’s investigational drug candidate Androxal was proven to increased testosterone and restore healthy sperm count in men with declining hormone levels due to secondary hypogonadism.  Based in The Woodlands, Texas, Repros Therapeutics is a development-stage biopharmaceutical company developing drug therapies for the treatment of serious female pelvic conditions, such as treatment of uterine fibroids, anemia associated with excessive menstrual bleeding relating to uterine fibroids, and anemia associated with uterine fibroids and endometriosis.  Repros Therapeutics has three late stage drug candidates in trials.

Trans World Entertainment Corporation (NASDAQ:TWMC) advanced 20.62% up to $1.17  on news the company’s CEO Robert Higgins bought 187,179 shares in the company from Oct. 2 to Oct. 6, at an average price of $0.096 per unit.  Headquartered in Albany, New York, Trans World Entertainment Corporation is a retail music, movie and video game franchise selling entertainment software, including music, video, video games, electronics, accessories and related products in US.

Timberline Resources Corp (AMEX:TLR) jumped 18.08% this morning up to $0.98 on no news.  As we reported earlier, the company is expected to disclose drilling study results of the Butte Highlands Gold Project within the next weeks.  Headquartered in Coeur d’Alene, Idaho Timberline Resources Corporation engages in the evaluation, acquisition, and exploration of mineral properties in the US. The company chiefly explores for gold, silver, zinc, and copper deposits in Montana, Nevada and Idaho.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  To view more of our profiled stocks, please visit us at PicksThatMove.com

Biotech And Biopharmaceutical Solutions Make Strong Gains In Late Morning

The hot stock information of the day includes:  PDEX, RPRX

Pro-Dex, Inc. (NASDAQ:PDEX) jumped 27.66% up to $0.60 on news the company released Q10 fiscal results late yesterday.  Despite a decline in sales of 4% over the last three month period of operations, and 16% decline in sales since June 2008; the company boasted gross profits for the quarter ended June 30, 2009 increasing to $1.9 million, a 35% gross profit margin. The company also reported a gross profit of $6.7 million, an increase of 32% compared to gross profit of $8.2 million or 33% gross profit margin for the year-ago period.  Operating expenses for the fourth quarter decreased by 27% to $1.7 million, compared to $2.2 million in the fourth quarter 2008. The company disclosed it has a $9.6 million backlog of orders and revealed a new product launch is coming soon. Based in Irvine, California, Pro-Dex Inc is a motion control and power engineering company providing high-tech and refined drive systems for the medical, dental, semiconductor, scientific research and aerospace markets worldwide.

Repros Therapeutics Inc. (Public, NASDAQ:RPRX) advanced 45.45% up to $1.28 on no official news.  Based in The Woodlands, Texas, Repros Therapeutics is a development-stage biopharmaceutical company developing drug therapies for the treatment of serious female pelvic conditions, such as treatment of uterine fibroids, anemia associated with excessive menstrual bleeding relating to uterine fibroids, and anemia associated with uterine fibroids and endometriosis.  Repros Therapeutics has three late stage drug candidates in trials.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock.